stoxline Quote Chart Rank Option Currency Glossary
  
CRISPR Therapeutics AG (CRSP)
67.95  -2.21 (-3.15%)    03-28 14:05
Open: 69.98
High: 70.12
Volume: 1,114,362
  
Pre. Close: 70.16
Low: 67.52
Market Cap: 5,721(M)
Technical analysis
2024-03-28 1:48:11 PM
Short term     
Mid term     
Targets 6-month :  95.53 1-year :  105.84
Resists First :  81.79 Second :  90.62
Pivot price 72.89
Supports First :  67.51 Second :  56.17
MAs MA(5) :  70.36 MA(20) :  75
MA(100) :  68.27 MA(250) :  58.6
MACD MACD :  -1.8 Signal :  -0.8
%K %D K(14,3) :  5.6 D(3) :  6.1
RSI RSI(14): 35.2
52-week High :  91.09 Low :  37.54
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CRSP ] has closed above bottom band by 4.4%. Bollinger Bands are 37% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 71.6 - 72.1 72.1 - 72.48
Low: 67.59 - 68.26 68.26 - 68.77
Close: 69.22 - 70.14 70.14 - 70.84
Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Headline News

Thu, 28 Mar 2024
ARK Investment Management LLC Boosts Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Thu, 28 Mar 2024
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of “Hold” by Brokerages - Defense World

Thu, 28 Mar 2024
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Thu, 28 Mar 2024
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.3% - MarketBeat

Tue, 26 Mar 2024
Biotech Roundtable: Is CRISPR all it's cracked up to be? (NASDAQ:CRSP) - Seeking Alpha

Tue, 26 Mar 2024
Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape (NASDAQ:CRSP) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -239 (M)
Shares Float 0 (M)
Held by Insiders 8.028e+007 (%)
Held by Institutions 7.919e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.95
Profit Margin -41.4 %
Operating Margin 34.5 %
Return on Assets (ttm) -6.3 %
Return on Equity (ttm) -8.2 %
Qtrly Rev. Growth 3 %
Gross Profit (p.s.) 0
Sales Per Share 2.03
EBITDA (p.s.) -4.84
Qtrly Earnings Growth -2.027e+008 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -35.07
Price to Sales 33.35
Price to Cash Flow 0
Stock Dividends
Dividend 1.506e+007
Forward Dividend 1.574e+007
Dividend Yield 22140500%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android